COPD

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Febbraio 29, 2024
Conference call, AstraZeneca, Research, New Drug Application, FDA, Quality of life, Marketing, EST, Growth, PDUFA, Travel, Conference, Chronic obstructive pulmonary disease, GMT, Hub, Safety, Information technology, Patient, Pharming, Clinical trial, Novartis, Disease, VRNA, IND, NDA, Head, Bromide, COPD, Pharmaceutical industry

LONDON and RALEIGH, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2023, and provides a corporate update.

Key Points: 
  • The debt facility provides non-dilutive capital and further financial flexibility to support Verona Pharma’s continued growth, including the commercialization of ensifentrine.
  • Net loss: Net loss was $14.1 million for the fourth quarter ended December 31, 2023 (Q4 2022: net loss $10.5 million).
  • Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EST / 2:00 p.m. GMT on Thursday, February 29, 2024, to discuss the fourth quarter and full year 2023 financial results and the corporate update.
  • An electronic copy of the fourth quarter and full year 2023 results press release will also be made available today on the Company’s website.

Third Pole Therapeutics Announces Successful Completion of Feasibility Study with eNOfit™ Portable Inhaled Nitric Oxide Delivery System

Retrieved on: 
Martedì, Febbraio 27, 2024
Oxygen, Pulmonary hypertension, Blood pressure, Blood, FDA, Quality of life, Gestational sac, Nitric oxide, Travel, Carbon, Lung, Medicine, Rest, Fatigue, Third Pole, Death, ILD, Patient, Artery, Heart, UCLA, Tissue, EFS, COPD

This study evaluated eNOfit™, a miniaturized, portable inhaled nitric oxide (iNO) generator and delivery system for the ambulatory treatment of patients suffering from pulmonary hypertension (PH) associated with Interstitial Lung Disease (ILD).

Key Points: 
  • This study evaluated eNOfit™, a miniaturized, portable inhaled nitric oxide (iNO) generator and delivery system for the ambulatory treatment of patients suffering from pulmonary hypertension (PH) associated with Interstitial Lung Disease (ILD).
  • “The successful completion of our EFS which validated the safe and practical use of our eNOfit™ system, enables us to confidently move into larger randomized placebo-controlled safety and efficacy studies.
  • Importantly, this value creating milestone will trigger the final funding of Third Pole’s Series B investment round.” said Bill Athenson, CEO of Third Pole.
  • Inhaled nitric oxide relaxes smooth muscle within the pulmonary vasculature, increasing the diameter of pulmonary arteries and decreasing their resistance to blood flow.

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation

Retrieved on: 
Venerdì, Febbraio 23, 2024
Regeneron Pharmaceuticals, Headache, Diarrhea, FDA, Food, Smoker, Back pain, Chronic obstructive pulmonary disease, Common, Safety, COVID-19, Patient, Priority, Disease, Diagnosis, Priority review, COPD, Pharmaceutical industry

TARRYTOWN, N.Y. and PARIS, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in a sixth potential indication as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD). The target action date for the FDA decision is June 27, 2024. Regulatory submissions are under review in China and Europe.

Key Points: 
  • The target action date for the FDA decision is June 27, 2024.
  • Regulatory submissions are under review in China and Europe.
  • In both trials, Dupixent rapidly and significantly improved lung function compared to placebo, with improvements sustained at 52 weeks.
  • Priority Review is granted to regulatory applications seeking approval for therapies that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions.

Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

Retrieved on: 
Venerdì, Febbraio 23, 2024
Eosinophil, Headache, Diarrhea, FDA, Food, Back pain, Chronic obstructive pulmonary disease, Common, European, Safety, COVID-19, Patient, Priority, Diagnosis, Smoker, COPD, Priority review

The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in a sixth potential indication as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD).

Key Points: 
  • The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in a sixth potential indication as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD).
  • The target action date for the FDA decision is June 27, 2024.
  • In both trials, Dupixent also rapidly and significantly improved lung function compared to placebo, with improvements sustained at 52 weeks.
  • Priority Review is granted to regulatory applications seeking approval for therapies that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions.

RS BioTherapeutics Creates Therapeutic Expert Council to Provide Guidance on Development of First-in-Class Agent Focused on Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

Retrieved on: 
Mercoledì, Febbraio 21, 2024
TEC, IPF, University, Idiopathic disease, Division, Assistant, Critical care, Idiopathic pulmonary fibrosis, Chronic obstructive pulmonary disease, Clinical research, Outline of health sciences, Consultant, Respiratory Medicine, Death, SUNY, Observation, Harvard Medical School, COPD, Pharmaceutical industry

CUMBERLAND, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce the formation of its Therapeutic Expert Council (TEC).

Key Points: 
  • CUMBERLAND, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce the formation of its Therapeutic Expert Council (TEC).
  • The TEC will help guide the development of RS BioTherapeutics’ first-in-class, steroid-free agent, RSBT-001, in development for Chronic Obstructive Pulmonary Disease (COPD), the third leading cause of death in the world; and Idiopathic Pulmonary Fibrosis (IPF), a rare disease with no cure that claims 40,000 lives each year in the U.S.
  • All have exceptional credentials and are uniquely qualified to help support the development of our first investigational compound, RSBT-001.
  • I’m excited to collaborate with them and look forward to engaging their diverse perspectives spanning the fields of COPD, IPF, and other diseases characterized by pulmonary inflammation.”

Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial

Retrieved on: 
Lunedì, Febbraio 26, 2024
Health, Medical Devices, Health Technology, Clinical Trials, Research, Science, Biotechnology, Foam, PMA, Teaching hospital, FDA, Quality of life, News, Food, IDE, American International Group, Chronic obstructive pulmonary disease, Safety, Lung, Endobronchial valve, Patient, Periodic breathing, Corporation, COPD, Fissure, Medical device

Successful treatment with the AeriSeal System is followed by treatment with commercially available Zephyr® Valves.

Key Points: 
  • Successful treatment with the AeriSeal System is followed by treatment with commercially available Zephyr® Valves.
  • Pulmonx received a staged IDE approval by the Food and Drug Administration (FDA) to commence the CONVERT II Pivotal Trial for the AeriSeal System in late 2023.
  • Severe COPD/emphysema patients with collateral ventilation confirmed with Pulmonx’s proprietary Chartis® Pulmonary Assessment System (Chartis) undergo the AeriSeal System treatment.
  • “We hope the CONVERT II Trial will move us closer to the goal of helping patients with collateral ventilation to also receive benefit from our Zephyr Valves.”

Global Respiratory Devices Market to Exhibit Strong Growth by 2027 - An In-depth Industry Analysis and Trends Overview - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Febbraio 26, 2024
Biotechnology, Health, Medical Devices, Personal protective equipment, Hospital, Growth, Conditional sentence, COVID-19, Air pollution, COPD

The Global Respiratory Devices market which grew at a robust CAGR from 2017-2022 & is forecasted to grow steadily from 2022-2027 driven by increase in respiratory illness cases, innovative technologies alongside growing inorganic growth strategies.

Key Points: 
  • The Global Respiratory Devices market which grew at a robust CAGR from 2017-2022 & is forecasted to grow steadily from 2022-2027 driven by increase in respiratory illness cases, innovative technologies alongside growing inorganic growth strategies.
  • The rapid growth in global geriatric population, rising incidents of chronic diseases (including COPD & asthma), alongside the cost advantage of home care devices & services are the key factors driving the global respiratory devices market.
  • The Global Respiratory Devices Market is fragmented with players occupying almost half of the market.
  • The Global Respiratory Devices Market witnessed significant growth during the period 2017-2022, owing to increase in fast fashion trends, Enhancing Service Offerings alongside increase in product innovativeness.

MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

Retrieved on: 
Venerdì, Febbraio 23, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Metabolism, AstraZeneca, Hypereosinophilic syndrome, Chronic pain, Growth, Skin, Fatigue, Immunology, Polyp (medicine), Efficacy, COPD, Biopharmaceutical, Social media, Placebo, Safety, Treatment, Chronic obstructive pulmonary disease, ClinicalTrials.gov, Abstract (summary), Respiratory Medicine, OCS, Bell, Rash, Biomarker, Heart, HES, Sinusitis, Inflammation, Weight loss, Asthma, Gastrointestinal tract, Death, OLE, Disease, Pharmaceutical industry

AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases.

Key Points: 
  • AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases.
  • Fasenra met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA).
  • Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.
  • A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (NATRON).

Global IV Catheters Market Insights Report 2023-2029: Peripheral Inserted Central Catheters (PICCs) Leading the Charge - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Febbraio 23, 2024
Medical Devices, Health, Diabetes, Incidence, Alzheimer's disease, Infection, ICU, USD, European, Ageing, Growth, Cancer, Conditional sentence, Stroke, Hospital, Government, Short, ICU Medical, Prevalence, Safety, Malaria, Nutrient, PICC, Life expectancy, Injury, Patient, Dementia, Tuberculosis, CVC, Developed country, COPD, Medical device

The global IV catheters market was valued at USD 4.93 billion in 2023 and is expected to reach a value of $6.64 billion by 2029, growing at a CAGR of 5.04%

Key Points: 
  • The global IV catheters market was valued at USD 4.93 billion in 2023 and is expected to reach a value of $6.64 billion by 2029, growing at a CAGR of 5.04%
    The global IV catheters market report contains exclusive data on 33 vendors.
  • BD, B Braun, Terumo, Teleflex, ICU Medical, and Nipro Medical are some leading players currently dominating the global IV catheters market.
  • The continuous growth in individuals with chronic conditions and the rapidly expanding elderly population are the primary factors fueling the global demand for peripheral IV catheters.
  • The peripheral inserted central catheters (PICCs) product segment accounted for the highest market share of over 45% of the global CIVCs market.

bioAffinity Technologies News Update

Retrieved on: 
Mercoledì, Febbraio 21, 2024
Oncology, Health, Biometrics, Health Technology, General Health, Biotechnology, BIAF, American Thoracic Society, Medicine, Sputum, Research, Fluid, Cole, Conference, Chronic obstructive pulmonary disease, Nursing care plan, Lung, BAL, ATS, Human, Associate, Patient, Lung cancer, Bronchoalveolar lavage, COPD, Evidence-based practice, Pharmaceutical industry

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.
  • Lung Innovations Network’s multidisciplinary team focuses on affordable, innovative and individualized care by incorporating new technologies and research into an evidence-based practice.
  • National Sales Director Dallas Coleman announced that Cole Koeppen has joined bioAffinity Technologies as Pulmonary Sales Executive for CyPath® Lung in North Texas.
  • Bansal’s experience as both clinician and researcher demonstrates his commitment to innovative healthcare and the best possible outcome for his patients,” bioAffinity Technologies President and CEO Maria Zannes said.